Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDX and CBT for Binge-Eating Disorder and Obesity
NCT03924193Phase 3Completed
- Sponsor
- Yale University
- Start
- Mar 2019
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lisdexamfetamine in binge eating disorder (BED) and obesity (3 arms), sponsored by Yale University. Primary endpoints: Binge-Eating Frequency at 3 months and Body Mass Index at 3 months. Started Mar 2019; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
binge eating disorder (BED)obesity
Beyond the preview
Go deeper on NCT03924193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03924193.